HUP0201722A2 - Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére - Google Patents

Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére Download PDF

Info

Publication number: HUP0201722A2
Authority: HU; Hungary
Prior art keywords: dichlorophenoxy; methylamine; alkyl; formula; ring
Prior art date: 2001-05-23

Application number

HU0201722A

Other languages

English (en)

Hungarian (hu)

Inventor

Harry Ralph Howard

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-23

Filing date

2002-05-22

Publication date

2003-07-28

2002-05-22 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2002-07-29 Publication of HU0201722D0 publication Critical patent/HU0201722D0/hu

2003-07-28 Publication of HUP0201722A2 publication Critical patent/HUP0201722A2/hu

Links

208000007848 Alcoholism Diseases 0.000 title claims abstract description 148
201000007930 alcohol dependence Diseases 0.000 title claims abstract description 147
239000008194 pharmaceutical composition Substances 0.000 title claims description 65
150000001875 compounds Chemical class 0.000 claims abstract description 239
150000003839 salts Chemical class 0.000 claims abstract description 102
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 51
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 46
125000000217 alkyl group Chemical group 0.000 claims abstract description 43
239000003401 opiate antagonist Substances 0.000 claims abstract description 38
125000005842 heteroatom Chemical group 0.000 claims abstract description 35
229910052799 carbon Inorganic materials 0.000 claims abstract description 31
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 30
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 30
125000001624 naphthyl group Chemical group 0.000 claims abstract description 29
125000001424 substituent group Chemical group 0.000 claims abstract description 29
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 26
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 17
229920006395 saturated elastomer Polymers 0.000 claims abstract description 15
125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 13
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 11
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 9
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 9
125000002837 carbocyclic group Chemical group 0.000 claims abstract description 7
125000005843 halogen group Chemical group 0.000 claims abstract description 5
-1 cyano, nitro, amino, hydroxyl Chemical group 0.000 claims description 145
238000000034 method Methods 0.000 claims description 72
238000011282 treatment Methods 0.000 claims description 67
229910052739 hydrogen Inorganic materials 0.000 claims description 58
239000001257 hydrogen Substances 0.000 claims description 57
239000004480 active ingredient Substances 0.000 claims description 41
239000000203 mixture Substances 0.000 claims description 35
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
150000002431 hydrogen Chemical class 0.000 claims description 27
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
241000124008 Mammalia Species 0.000 claims description 26
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 25
229910052731 fluorine Inorganic materials 0.000 claims description 25
239000011737 fluorine Substances 0.000 claims description 25
229910052736 halogen Inorganic materials 0.000 claims description 19
150000002367 halogens Chemical group 0.000 claims description 19
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
229910052760 oxygen Inorganic materials 0.000 claims description 17
BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 16
229910052717 sulfur Inorganic materials 0.000 claims description 16
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
239000003937 drug carrier Substances 0.000 claims description 14
239000001301 oxygen Substances 0.000 claims description 14
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 13
239000011593 sulfur Substances 0.000 claims description 13
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 10
125000003282 alkyl amino group Chemical group 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 8
HYLYTRKKGFVHIE-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 HYLYTRKKGFVHIE-UHFFFAOYSA-N 0.000 claims description 7
125000000304 alkynyl group Chemical group 0.000 claims description 7
125000004434 sulfur atom Chemical group 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
AAQZZAVVFRIEOD-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-4-(trifluoromethyl)phenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC=C(C(F)(F)F)C=C1OC1=CC=C(Cl)C(Cl)=C1 AAQZZAVVFRIEOD-UHFFFAOYSA-N 0.000 claims description 3
BWBOBCUPLKYBOV-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-4-methoxyphenyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=C(CN(C)C)C(OC=2C=C(Cl)C(Cl)=CC=2)=C1 BWBOBCUPLKYBOV-UHFFFAOYSA-N 0.000 claims description 3
KBGXEJXXNBUUKO-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-4-phenylphenyl]-n-methylmethanamine Chemical compound CNCC1=CC=C(C=2C=CC=CC=2)C=C1OC1=CC=C(Cl)C(Cl)=C1 KBGXEJXXNBUUKO-UHFFFAOYSA-N 0.000 claims description 3
VTOCPMQDJCNXJC-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(4-fluorophenyl)phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C=2C=CC(F)=CC=2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 VTOCPMQDJCNXJC-UHFFFAOYSA-N 0.000 claims description 3
MRHLSXLWXQUUIW-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(4-methylphenyl)phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C=2C=CC(C)=CC=2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 MRHLSXLWXQUUIW-UHFFFAOYSA-N 0.000 claims description 3
WDOHSBCURHURPV-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(triazol-1-yl)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(N2N=NC=C2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 WDOHSBCURHURPV-UHFFFAOYSA-N 0.000 claims description 3
YJHCOYWCYPKAQN-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(C(F)(F)F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 YJHCOYWCYPKAQN-UHFFFAOYSA-N 0.000 claims description 3
MCCUQEYBDREHCZ-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 MCCUQEYBDREHCZ-UHFFFAOYSA-N 0.000 claims description 3
FQEBOQLYHASAOY-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-n-methylmethanamine Chemical compound CNCC1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 FQEBOQLYHASAOY-UHFFFAOYSA-N 0.000 claims description 3
ARYNSJMHZVVGNH-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-methylphenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(C)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 ARYNSJMHZVVGNH-UHFFFAOYSA-N 0.000 claims description 3
PMXOUAJLQYBUOO-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-fluorophenyl]-n-methylmethanamine Chemical compound CNCC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1 PMXOUAJLQYBUOO-UHFFFAOYSA-N 0.000 claims description 3
MNHWUSSFFCLNEP-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC=CC=C1OC1=CC=C(Cl)C=C1 MNHWUSSFFCLNEP-UHFFFAOYSA-N 0.000 claims description 3
CBFOMONXEQWNRB-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]piperidin-2-one Chemical compound CNCC1=CC(N2C(CCCC2)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 CBFOMONXEQWNRB-UHFFFAOYSA-N 0.000 claims description 3
FZCQKTZYKUFNAJ-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]pyrazol-3-amine Chemical compound CNCC1=CC(N2N=C(N)C=C2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 FZCQKTZYKUFNAJ-UHFFFAOYSA-N 0.000 claims description 3
WJYRLEWZANLZLM-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]pyrrolidin-2-one Chemical compound CNCC1=CC(N2C(CCC2)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 WJYRLEWZANLZLM-UHFFFAOYSA-N 0.000 claims description 3
XKFGLVWDKDNTGI-UHFFFAOYSA-N 1-[5-bromo-2-(3,4-dichlorophenoxy)phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(Br)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 XKFGLVWDKDNTGI-UHFFFAOYSA-N 0.000 claims description 3
QFWNAKAETMKRTM-UHFFFAOYSA-N 3-(3,4-dichlorophenoxy)-4-(methylaminomethyl)benzonitrile Chemical compound CNCC1=CC=C(C#N)C=C1OC1=CC=C(Cl)C(Cl)=C1 QFWNAKAETMKRTM-UHFFFAOYSA-N 0.000 claims description 3
ZPJJDPPFWWSPPB-UHFFFAOYSA-N 4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)benzonitrile Chemical compound CNCC1=CC(C#N)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 ZPJJDPPFWWSPPB-UHFFFAOYSA-N 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
GQNWCHJJMVQERW-UHFFFAOYSA-N n-[3-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]phenyl]acetamide Chemical compound CNCC1=CC(C=2C=C(NC(C)=O)C=CC=2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 GQNWCHJJMVQERW-UHFFFAOYSA-N 0.000 claims description 3
ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 3
KCRBGCHPNCBUCW-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-phenylphenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C=2C=CC=CC=2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 KCRBGCHPNCBUCW-UHFFFAOYSA-N 0.000 claims description 2
QFDTVBGMNGXZGK-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)phenyl]-n,n-dimethylethanamine Chemical compound CN(C)C(C)C1=CC=CC=C1OC1=CC=C(Cl)C(Cl)=C1 QFDTVBGMNGXZGK-UHFFFAOYSA-N 0.000 claims description 2
WJHPAIHCWWZGFM-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-fluorophenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1 WJHPAIHCWWZGFM-UHFFFAOYSA-N 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
KZLLRXARLPOUMH-UHFFFAOYSA-N n-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]acetamide Chemical compound CN(C)CC1=CC(NC(C)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 KZLLRXARLPOUMH-UHFFFAOYSA-N 0.000 claims description 2
SOCXCXJYEMOKAM-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-4-(1,2,4-triazol-1-yl)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC=C(N2N=CN=C2)C=C1OC1=CC=C(Cl)C(Cl)=C1 SOCXCXJYEMOKAM-UHFFFAOYSA-N 0.000 claims 2
QLTUAGOAYVRRPQ-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(1,3-thiazol-2-yl)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(C=2SC=CN=2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 QLTUAGOAYVRRPQ-UHFFFAOYSA-N 0.000 claims 2
ULJOCBVUVYUVEY-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(triazol-2-yl)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(N2N=CC=N2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 ULJOCBVUVYUVEY-UHFFFAOYSA-N 0.000 claims 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
LWHZIZQQEKJCCP-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC=CC=C1OC1=CC=C(Cl)C(Cl)=C1 LWHZIZQQEKJCCP-UHFFFAOYSA-N 0.000 claims 1
QGLOKMBXFYKGID-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)-3-[1-(methylamino)ethyl]phenyl]pyrrolidin-2-one Chemical compound CNC(C)C1=CC(N2C(CCC2)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 QGLOKMBXFYKGID-UHFFFAOYSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 33
125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 33
238000006243 chemical reaction Methods 0.000 description 31
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
239000000243 solution Substances 0.000 description 23
229940126403 monoamine reuptake inhibitor Drugs 0.000 description 22
SYJXFKPQNSDJLI-HKEUSBCWSA-N neamine Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N SYJXFKPQNSDJLI-HKEUSBCWSA-N 0.000 description 22
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
208000035475 disorder Diseases 0.000 description 16
239000003887 narcotic antagonist Substances 0.000 description 16
230000000694 effects Effects 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
201000010099 disease Diseases 0.000 description 14
239000002253 acid Substances 0.000 description 13
230000009471 action Effects 0.000 description 13
239000000543 intermediate Substances 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
238000003556 assay Methods 0.000 description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
150000001721 carbon Chemical group 0.000 description 11
239000000839 emulsion Substances 0.000 description 11
238000009472 formulation Methods 0.000 description 11
125000006239 protecting group Chemical group 0.000 description 11
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000002585 base Substances 0.000 description 10
239000002609 medium Substances 0.000 description 10
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 10
239000003826 tablet Substances 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000000460 chlorine Substances 0.000 description 9
229910052801 chlorine Inorganic materials 0.000 description 9
229960003638 dopamine Drugs 0.000 description 9
150000001299 aldehydes Chemical group 0.000 description 8
239000007853 buffer solution Substances 0.000 description 8
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
WWPITPSIWMXDPE-UHFFFAOYSA-N para-chloroamphetamine Chemical compound CC(N)CC1=CC=C(Cl)C=C1 WWPITPSIWMXDPE-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
229910052740 iodine Inorganic materials 0.000 description 7
150000003951 lactams Chemical group 0.000 description 7
230000000407 monoamine reuptake Effects 0.000 description 7
229960002748 norepinephrine Drugs 0.000 description 7
229940076279 serotonin Drugs 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 6
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
239000000556 agonist Substances 0.000 description 6
238000009739 binding Methods 0.000 description 6
230000037396 body weight Effects 0.000 description 6
108700023159 delta Opioid Receptors Proteins 0.000 description 6
102000048124 delta Opioid Receptors Human genes 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000011630 iodine Substances 0.000 description 6
150000002576 ketones Chemical class 0.000 description 6
RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 6
150000002825 nitriles Chemical class 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
230000027455 binding Effects 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
125000004122 cyclic group Chemical group 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000003921 oil Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
238000012360 testing method Methods 0.000 description 5
PZWWYAHWHHNCHO-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 PZWWYAHWHHNCHO-FGHAYEPSSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 4
APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
239000012442 inert solvent Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
229960004127 naloxone Drugs 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
108700040302 phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide Proteins 0.000 description 4
238000011084 recovery Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 3
MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
101100108551 Mus musculus Akr1b7 gene Proteins 0.000 description 3
WIYUZYBFCWCCQJ-IFKAHUTRSA-N Naltrindole Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3NC=25)O)CC1)O)CC1CC1 WIYUZYBFCWCCQJ-IFKAHUTRSA-N 0.000 description 3
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
PGZRDDYTKFZSFR-ONTIZHBOSA-N U69593 Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=CC=CC=2)C[C@]21CCCO2 PGZRDDYTKFZSFR-ONTIZHBOSA-N 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000003710 cerebral cortex Anatomy 0.000 description 3
238000004891 communication Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229960005297 nalmefene Drugs 0.000 description 3
229960000938 nalorphine Drugs 0.000 description 3
229960003086 naltrexone Drugs 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000008159 sesame oil Substances 0.000 description 3
235000011803 sesame oil Nutrition 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
235000017550 sodium carbonate Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
210000003568 synaptosome Anatomy 0.000 description 3
150000003536 tetrazoles Chemical class 0.000 description 3
230000009466 transformation Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
KQWVAUSXZDRQPZ-UMTXDNHDSA-N 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enyl-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 description 2
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108010092674 Enkephalins Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000028505 alcohol-related disease Diseases 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
150000003950 cyclic amides Chemical class 0.000 description 2
INUCRGMCKDQKNA-CEMLEFRQSA-N cyprodime Chemical compound N1([C@@H]2CC=3C=CC=C(C=3[C@@]3([C@]2(CCC(=O)C3)OC)CC1)OC)CC1CC1 INUCRGMCKDQKNA-CEMLEFRQSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000012055 enteric layer Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000007789 gas Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
102000048260 kappa Opioid Receptors Human genes 0.000 description 2
239000008101 lactose Substances 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
102000051367 mu Opioid Receptors Human genes 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000006187 pill Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
235000012431 wafers Nutrition 0.000 description 2
108020001588 κ-opioid receptors Proteins 0.000 description 2
108020001612 μ-opioid receptors Proteins 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
UZHSEJADLWPNLE-OGLQFSJHSA-N (4R,4aS,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O1C2C(=O)CC[C@@]3(O)[C@]4([H])N(CC=C)CC[C@]23C2=C1C(O)=CC=C2C4 UZHSEJADLWPNLE-OGLQFSJHSA-N 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
UBHFJRNWKGLSAW-UHFFFAOYSA-N 1-(5-imidazol-1-yl-2-naphthalen-2-yloxyphenyl)-n,n-dimethylmethanamine Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CN(C)C)=CC=1N1C=CN=C1 UBHFJRNWKGLSAW-UHFFFAOYSA-N 0.000 description 1
CBVMSOILTQVWFP-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-(1-methyltetrazol-5-yl)phenyl]-n,n-dimethylethanamine Chemical compound CN(C)C(C)C1=CC(C=2N(N=NN=2)C)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 CBVMSOILTQVWFP-UHFFFAOYSA-N 0.000 description 1
IBQGQTKTKQIZKP-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxyphenyl]-n-methylmethanamine Chemical compound CNCC1=CC(F)=C(OC)C=C1OC1=CC=C(Cl)C(Cl)=C1 IBQGQTKTKQIZKP-UHFFFAOYSA-N 0.000 description 1
GNUZEERROYMPLI-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-n,n-dimethylcyclopropan-1-amine Chemical compound C=1C(F)=CC=C(OC=2C=C(Cl)C(Cl)=CC=2)C=1C1(N(C)C)CC1 GNUZEERROYMPLI-UHFFFAOYSA-N 0.000 description 1
FTANDNLTKJAUPS-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-methylsulfanylphenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(SC)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 FTANDNLTKJAUPS-UHFFFAOYSA-N 0.000 description 1
GPMJGIFHVAAPIF-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-methylsulfanylphenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(SC)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 GPMJGIFHVAAPIF-UHFFFAOYSA-N 0.000 description 1
UGPOJQLUCQGPBD-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-methylsulfinylphenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(S(C)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 UGPOJQLUCQGPBD-UHFFFAOYSA-N 0.000 description 1
CHTPKHGDXWZUTL-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenoxy)-5-methylsulfonylphenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 CHTPKHGDXWZUTL-UHFFFAOYSA-N 0.000 description 1
RBBPLEJTJYWGTE-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-(1,2,4-triazol-4-yl)phenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(N2C=NN=C2)=CC=C1OC1=CC=C(Cl)C=C1 RBBPLEJTJYWGTE-UHFFFAOYSA-N 0.000 description 1
MJXYTTAAIBVYCB-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-(1-methylpyrrol-3-yl)phenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(C2=CN(C)C=C2)=CC=C1OC1=CC=C(Cl)C=C1 MJXYTTAAIBVYCB-UHFFFAOYSA-N 0.000 description 1
IFULASKOIFNZJK-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-(1-methyltetrazol-5-yl)phenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(C=2N(N=NN=2)C)=CC=C1OC1=CC=C(Cl)C=C1 IFULASKOIFNZJK-UHFFFAOYSA-N 0.000 description 1
KHULKJQKNMFLOO-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-(5-methyltetrazol-1-yl)phenyl]-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC(N2C(=NN=N2)C)=CC=C1OC1=CC=C(Cl)C=C1 KHULKJQKNMFLOO-UHFFFAOYSA-N 0.000 description 1
QMAXNWNIZKBGER-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl]-n-methylethanamine Chemical compound CNC(C)C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(Cl)C=C1 QMAXNWNIZKBGER-UHFFFAOYSA-N 0.000 description 1
RQDLNRGGJROPPR-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]-3-methyl-1,3-diazinan-2-one Chemical compound CNCC1=CC(N2C(N(C)CCC2)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 RQDLNRGGJROPPR-UHFFFAOYSA-N 0.000 description 1
CCSCGUWEJSYZNZ-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]-3-methylimidazolidin-2-one Chemical compound CNCC1=CC(N2C(N(C)CC2)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 CCSCGUWEJSYZNZ-UHFFFAOYSA-N 0.000 description 1
FJBCXFCOHTUVAN-UHFFFAOYSA-N 1-[5-chloro-2-(3,4-dichlorophenoxy)phenyl]-n-methylpropan-1-amine Chemical compound CCC(NC)C1=CC(Cl)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 FJBCXFCOHTUVAN-UHFFFAOYSA-N 0.000 description 1
WIRTYVYQEXTSIB-UHFFFAOYSA-N 1-[5-fluoro-2-(4-fluoro-3-methoxyphenoxy)phenyl]-n,n-dimethylmethanamine Chemical compound C1=C(F)C(OC)=CC(OC=2C(=CC(F)=CC=2)CN(C)C)=C1 WIRTYVYQEXTSIB-UHFFFAOYSA-N 0.000 description 1
KPFYMIPQCXAYKS-UHFFFAOYSA-N 1-methyl-3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]-1,3-diazinan-2-one Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1CCCN(C)C1=O KPFYMIPQCXAYKS-UHFFFAOYSA-N 0.000 description 1
JGPJINZMHOSMII-UHFFFAOYSA-N 1-methyl-3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]imidazolidin-2-one Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1CCN(C)C1=O JGPJINZMHOSMII-UHFFFAOYSA-N 0.000 description 1
BOMHEGKEVBTRBL-UHFFFAOYSA-N 1-methyl-3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]imidazolidine-2,4-dione Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1C(=O)CN(C)C1=O BOMHEGKEVBTRBL-UHFFFAOYSA-N 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
JJKYQHMJQAMHKF-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenoxy)-5-(5-methylthiadiazol-4-yl)phenyl]ethanamine Chemical compound S1N=NC(C=2C=C(CCN)C(OC=3C=C(Cl)C(Cl)=CC=3)=CC=2)=C1C JJKYQHMJQAMHKF-UHFFFAOYSA-N 0.000 description 1
PTHWEAVZUFLNTB-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,2-dimethylpiperidine Chemical compound CN1CCCCC1(C)C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 PTHWEAVZUFLNTB-UHFFFAOYSA-N 0.000 description 1
PKDAKELWMBRZFQ-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1,5-dimethylpyrrolidine Chemical compound CN1C(C)CCC1C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 PKDAKELWMBRZFQ-UHFFFAOYSA-N 0.000 description 1
OXYPLWPQQDDYFW-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-1-methylpiperidine Chemical compound CN1CCCCC1C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 OXYPLWPQQDDYFW-UHFFFAOYSA-N 0.000 description 1
ZKWNWOMNZUTWAF-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]piperidine Chemical compound C1CCCNC1C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 ZKWNWOMNZUTWAF-UHFFFAOYSA-N 0.000 description 1
SJTQXWBXLFJXNA-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenoxy)-5-methylsulfanylphenyl]-n-methylpropan-2-amine Chemical compound CNC(C)(C)C1=CC(SC)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 SJTQXWBXLFJXNA-UHFFFAOYSA-N 0.000 description 1
LRTGJDBHLQJBNH-UHFFFAOYSA-N 2-[4-chloro-2-(3,4-dichlorophenoxy)-5-methylsulfonylphenyl]ethanamine Chemical compound CS(=O)(=O)C1=C(C=C(C(=C1)CCN)OC2=CC(=C(C=C2)Cl)Cl)Cl LRTGJDBHLQJBNH-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical class FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
CFCFNOBVEQYCRG-UHFFFAOYSA-N 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methylmorpholine Chemical compound CN1CCOCC1C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 CFCFNOBVEQYCRG-UHFFFAOYSA-N 0.000 description 1
LFTUZGHRTOFCPA-UHFFFAOYSA-N 3-[2-(3,4-dichlorophenoxy)-5-fluorophenyl]-4-methylthiomorpholine Chemical compound CN1CCSCC1C1=CC(F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 LFTUZGHRTOFCPA-UHFFFAOYSA-N 0.000 description 1
VCWUFWSDFBJEQI-UHFFFAOYSA-N 3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]-1,3-oxazolidin-2-one Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1CCOC1=O VCWUFWSDFBJEQI-UHFFFAOYSA-N 0.000 description 1
ZFRYGKBVPCZLJN-UHFFFAOYSA-N 3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]-1,3-oxazolidine-2,4-dione Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1C(=O)COC1=O ZFRYGKBVPCZLJN-UHFFFAOYSA-N 0.000 description 1
CRLPHIQRZBJONV-UHFFFAOYSA-N 3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]-1,3-thiazolidin-2-one Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1CCSC1=O CRLPHIQRZBJONV-UHFFFAOYSA-N 0.000 description 1
BXMDAAMKQKMCDJ-UHFFFAOYSA-N 3-[3-(methylaminomethyl)-4-naphthalen-2-yloxyphenyl]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C(OC=2C=C3C=CC=CC3=CC=2)C(CNC)=CC=1N1C(=O)CSC1=O BXMDAAMKQKMCDJ-UHFFFAOYSA-N 0.000 description 1
QZHYCJAXBITRRZ-UHFFFAOYSA-N 3-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]-1,3-thiazolidin-2-one Chemical compound CNCC1=CC(N2C(SCC2)=O)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 QZHYCJAXBITRRZ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
NVXGKVLUJXXCLR-UHFFFAOYSA-N 4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]-n,n-dimethylaniline Chemical compound CN(C)CC1=CC(N(C)C)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 NVXGKVLUJXXCLR-UHFFFAOYSA-N 0.000 description 1
YZHISSCBAUQDOP-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenoxy)-3-(1-methylpyrrolidin-2-yl)phenyl]-2-methylpyrimidine Chemical compound CN1CCCC1C1=CC(C=2N=C(C)N=CC=2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 YZHISSCBAUQDOP-UHFFFAOYSA-N 0.000 description 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010001605 Alcohol poisoning Diseases 0.000 description 1
208000017167 Alcohol-Induced disease Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
206010012225 Delirium tremens Diseases 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010021403 Illusion Diseases 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
244000258044 Solanum gilo Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
NJVHJTQSGGRHGP-UHFFFAOYSA-K [Li].[Al+3].[Cl-].[Cl-].[Cl-] Chemical compound [Li].[Al+3].[Cl-].[Cl-].[Cl-] NJVHJTQSGGRHGP-UHFFFAOYSA-K 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
208000029650 alcohol withdrawal Diseases 0.000 description 1
208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003109 amnesic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
125000004069 aziridinyl group Chemical group 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
210000001653 corpus striatum Anatomy 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000000841 delta opiate receptor agonist Substances 0.000 description 1
239000000857 delta opiate receptor antagonist Substances 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000028436 dopamine uptake Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000020375 flavoured syrup Nutrition 0.000 description 1
UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical compound [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000002623 mu opiate receptor antagonist Substances 0.000 description 1
230000025712 muscle attachment Effects 0.000 description 1
229960005250 naloxone hydrochloride Drugs 0.000 description 1
RHBRMCOKKKZVRY-ITLPAZOVSA-N naltrexone hydrochloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 RHBRMCOKKKZVRY-ITLPAZOVSA-N 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
229940065778 narcan Drugs 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000019818 neurotransmitter uptake Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
125000002560 nitrile group Chemical group 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
229960001073 nomifensine Drugs 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
230000012154 norepinephrine uptake Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
125000000466 oxiranyl group Chemical group 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
229940116238 revex Drugs 0.000 description 1
229940110294 revia Drugs 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000005503 thioxanyl group Chemical group 0.000 description 1
VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000000844 transformation Methods 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HU0201722A 2001-05-23 2002-05-22 Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére HUP0201722A2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29308801P	2001-05-23	2001-05-23

Publications (2)

Publication Number	Publication Date
HU0201722D0 HU0201722D0 (th)	2002-07-29
HUP0201722A2 true HUP0201722A2 (hu)	2003-07-28

Family

ID=23127615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0201722A HUP0201722A2 (hu)	2001-05-23	2002-05-22	Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére

Country Status (11)

Country	Link
US (2)	US20030130322A1 (th)
EP (1)	EP1262196A3 (th)
JP (1)	JP2002370975A (th)
KR (1)	KR20020090153A (th)
CN (1)	CN1386503A (th)
AU (1)	AU4068602A (th)
CA (1)	CA2386740A1 (th)
HU (1)	HUP0201722A2 (th)
NZ (1)	NZ519032A (th)
PL (1)	PL354110A1 (th)
ZA (1)	ZA200204019B (th)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101167579B1 (ko) *	2003-04-29	2012-07-27	오렉시젠 세러퓨틱스 인크.	체중감량용 조성물
US8758443B2 (en)	2005-05-06	2014-06-24	Titan Spine, Llc	Implants with integration surfaces having regular repeating surface patterns
PT2135603E (pt)	2005-11-22	2013-04-03	Orexigen Therapeutics Inc	Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
JP2009517393A (ja) *	2005-11-28	2009-04-30	オレキシジェン・セラピューティクス・インコーポレーテッド	不安症の治療方法
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
WO2008060964A2 (en)	2006-11-09	2008-05-22	Orexigen Therapeutics, Inc.	Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de)	2006-11-09	2010-04-29	Orexigen Therapeutics Inc	Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
MX2009006672A (es) *	2006-12-19	2009-10-26	Univ Virginia	Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
KR20100127799A (ko)	2008-02-28	2010-12-06	유니버시티 오브 버지니아 페이턴트 파운데이션	세로토닌 운반체 유전자 및 알콜중독의 치료
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL2801625T3 (pl)	2010-07-02	2018-06-29	University Of Virginia Patent Foundation	Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków
EP2751137A4 (en)	2011-09-09	2015-06-03	Univ Virginia Patent Found	MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
PL4104824T3 (pl)	2012-06-06	2025-11-12	Nalpropion Pharmaceuticals Llc	Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN114588467B (zh) *	2022-04-01	2022-11-29	广州蓝仕威克医疗科技有限公司	一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) *	2022-12-29	2023-04-04	文韬创新药物研究（北京）有限责任公司	用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA923283B (en) *	1991-05-29	1993-01-27	Akzo Nv	Phenoxyphenyl derivatives
DK0782445T3 (da) *	1994-09-19	2002-05-06	Bristol Myers Squibb Pharma Co	Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
US5948807A (en) *	1997-09-03	1999-09-07	Regents Of The University Of Minnesota	Spiroindanamines and Spiroindanimides
EP0945133A1 (en) *	1998-03-26	1999-09-29	Lipha	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
YU56301A (sh) *	1999-02-23	2004-05-12	Pfizer Products Inc.	Inhibitori resorpcije monoamina za tretiranje poremećaja cns
US6071918A (en) *	1999-07-21	2000-06-06	Dupont Pharmaceuticals Company	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
SK4732002A3 (en) *	1999-10-13	2002-12-03	Pfizer Prod Inc	Biaryl ether derivatives useful as monoamine reuptake inhibitors

2002
- 2002-05-02 EP EP02253105A patent/EP1262196A3/en not_active Withdrawn
- 2002-05-08 JP JP2002132804A patent/JP2002370975A/ja not_active Withdrawn
- 2002-05-16 AU AU40686/02A patent/AU4068602A/en not_active Abandoned
- 2002-05-17 NZ NZ519032A patent/NZ519032A/en unknown
- 2002-05-17 CA CA002386740A patent/CA2386740A1/en not_active Abandoned
- 2002-05-21 ZA ZA200204019A patent/ZA200204019B/xx unknown
- 2002-05-22 HU HU0201722A patent/HUP0201722A2/hu unknown
- 2002-05-22 US US10/153,379 patent/US20030130322A1/en not_active Abandoned
- 2002-05-23 KR KR1020020028682A patent/KR20020090153A/ko not_active Ceased
- 2002-05-23 CN CN02120350A patent/CN1386503A/zh active Pending
- 2002-05-23 PL PL02354110A patent/PL354110A1/xx not_active Application Discontinuation
2004
- 2004-02-20 US US10/783,196 patent/US20040162316A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HU0201722D0 (th)	2002-07-29
JP2002370975A (ja)	2002-12-24
EP1262196A2 (en)	2002-12-04
EP1262196A3 (en)	2002-12-18
US20030130322A1 (en)	2003-07-10
PL354110A1 (en)	2002-12-02
US20040162316A1 (en)	2004-08-19
KR20020090153A (ko)	2002-11-30
ZA200204019B (en)	2003-11-21
CA2386740A1 (en)	2002-11-23
CN1386503A (zh)	2002-12-25
AU4068602A (en)	2002-12-05
NZ519032A (en)	2003-10-31

Legal Events

Date	Code	Title	Description
2006-02-28	FD9A	Lapse of provisional protection due to non-payment of fees

Publication	Publication Date	Title
CN100406011C (zh)	2008-07-30	含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物
US20030130322A1 (en)	2003-07-10	Combination treatment for alcoholism and alcohol dependence
JPH11506472A (ja)	1999-06-08	５―ｈｔ１ａおよび／または５―ｈｔ１ｄ受容体の選択的（アンタ）アゴニストとしてのベンジル（イデン）―ラクタム誘導体、その調製法及びその使用法
JP4399862B2 (ja)	2010-01-20	腸疾患および内臓痛の治療薬
JP2001302546A (ja)	2001-10-31	Ｉｉ型糖尿病を発症する危険性の高い個体を予防的に処置する方法
CN107847499A (zh)	2018-03-27	治疗神经退行性疾病的方法
US7566728B2 (en)	2009-07-28	Remedy for sleep disturbance
JP2019523269A (ja)	2019-08-22	睡眠障害の治療及び予防
JP2004504376A (ja)	2004-02-12	医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ
CA2554617A1 (en)	2005-08-04	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
JP2002523506A (ja)	2002-07-30	肥満の処置のためのピロロキノリン
US20080138413A1 (en)	2008-06-12	Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
JP4890710B2 (ja)	2012-03-07	ピリドモルフィナン類、チエノモルフィナン類及びそれらの使用
TW200825067A (en)	2008-06-16	CB1 compounds
JP2021511338A (ja)	2021-05-06	睡眠障害の治療及び予防
WO2008075162A2 (en)	2008-06-26	Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
TW589181B (en)	2004-06-01	Lymphocytic activation inhibitor and remedial agent for autoimmune disease
JP3332233B2 (ja)	2002-10-07	ドラッグ及び物質の乱用による中毒の治療
HUP0201720A2 (hu)	2003-07-28	Szorongás és depresszió kezelésére szolgáló kombinált készítmények és alkalmazásuk
US20020077323A1 (en)	2002-06-20	Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies
CN114144179A (zh)	2022-03-04	含血清素的试剂和5-ht1a受体拮抗剂
US20080139615A1 (en)	2008-06-12	Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof
HK40065810A (en)	2022-08-05	Serotonergic agent and 5-ht1a-receptor antagonist
HK1050479A (en)	2003-06-27	Combination treatment for alcoholism and alcohol dependence